These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27030185)

  • 1. [Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis].
    Semiserin VA; Karakozov AG; Malkuta MA; Zolotareva LA; Levchenko OB; Kalyagin IE; Eremin MN
    Ter Arkh; 2016; 88(2):58-63. PubMed ID: 27030185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [THE USE OF REMAXOL IN THE TREATMENT OF METABOLIC SYNDROME IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND DIABETES MELLITUS 2 TYPE].
    Dudorenko SV; Kovalenko AL; Prokopenko SM; Belogurova EV
    Eksp Klin Gastroenterol; 2016; (6):89-94. PubMed ID: 30280846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy].
    Stel'makh VV; Kozlov VK
    Ter Arkh; 2013; 85(4):71-6. PubMed ID: 23808297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenetic therapy of metabolic syndrome at the stage of visceral lesions].
    Stel'makh VV; Kozlov VK; Radchenko VG; Nekrasova AS
    Klin Med (Mosk); 2012; 90(6):61-5. PubMed ID: 22997724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of Remaxol on the efficiency of standard treatment for infiltrative pulmonary tuberculosis].
    Volchegorsky IA; Novoselov PN; Ushkareva EV
    Ter Arkh; 2016; 88(3):73-78. PubMed ID: 27030334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the effect of remaxol on hepatocytes in non-alcoholic fatty liver dystrophy modeling in laboratory C57BL/6 mice].
    Pritulina YG; Prokopenko SE; Kordenko AA; Atiakshin DA; Lobanov VL
    Arkh Patol; 2019; 81(5):64-69. PubMed ID: 31626206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.
    Li YH; Yang LH; Sha KH; Liu TG; Zhang LG; Liu XX
    World J Gastroenterol; 2015 Jun; 21(22):7008-13. PubMed ID: 26078579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
    Kim GH; Chung JW; Lee JH; Ok KS; Jang ES; Kim J; Shin CM; Park YS; Hwang JH; Jeong SH; Kim N; Lee DH; Kim JW
    Clin Mol Hepatol; 2015 Dec; 21(4):379-86. PubMed ID: 26770927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
    Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
    Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
    Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PLACE REMAXOL AS A HEPATOPROTECTOR IN INTENSIVE THERAPY OF PERVASIVE PERITONITIS].
    Orlov YP; Lukach VN; Govorova NV; Gluschenko AV; Dmitriva OD
    Anesteziol Reanimatol; 2015; 60(6):24-9. PubMed ID: 27025129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
    Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage].
    Bokhan NA; Abolonin AF; Ankudinova IÉ; Kurgak DI; Mandel' AI
    Ter Arkh; 2012; 84(10):51-5. PubMed ID: 23227501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [[Features of Pharmacological Correction of Alcoholic Fatty Liver Disease in Patients with Acute Ethanol Intoxication].].
    Livanov GA; Shikalova IA; Lodyagin AN; Glushkov S; Batotsyrenov BV; Loladze AT; Kovalenko AL
    Eksp Klin Gastroenterol; 2016; (5):45-50. PubMed ID: 28614644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
    Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
    Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.